by sfrazee | Jun 10, 2023
This policy brief reviews the evidence on the health and cost impacts of multi-cancer early detection (MCED) tests, and the implications for proposed legislation to enhance their utilization in Medicare. We find that the evidence base suggests that MCED screening...
by sfrazee | Dec 23, 2022
This Policy Brief analyzes the impact of The Inflation Reduction Act (IRA) on generic and biosimilar competition. We first review the large savings that generic and biosimilar competition entails in the U.S., which is threatened by competitors’ uncertain investments....
by sfrazee | Oct 26, 2022
This paper assesses the value of take-home Alzheimer’s dementia (AD) treatments over physician-administered ones. We find that shifting from a physician-administered treatment to a home-based one in the US would generate a value of $4.67 billion to $25.51 billion...
